An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer

Japanese Journal of Clinical Oncology

Volumn 35, Issue 9, 2005, Pages 536-544

  Sakamoto, Junichi ^a   Hamada, Chikuma ^a   Rahman, Mahbubur ^a   Kodaira, Susumu ^a   Ito, Katsuki ^a   Nakazato, Hiroaki ^a   Ohashi, Yasuo ^a   Yasutomi, Masayuki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Carmofur; Chemotherapy; Colorectal cancer; Disease free survival; Overall survival; Randomized clinical trials

Indexed keywords

CARMOFUR; MITOMYCIN C; PICIBANIL;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLON RESECTION; CONFIDENCE INTERVAL; DRUG EFFICACY; FOLLOW UP; HUMAN; INFORMATION RETRIEVAL; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE;

EID: 27644586383     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi147     Document Type: Article

References (67)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37(Suppl 3):S4-S66.
2. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
3. Meta-Analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8.
4. Meta-Analysis Group In Cancer. Toxicity of 5-fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 1998;16:1-6.
5. Wolmark N, Rockette H, Mamovnas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovolin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes'B and C carcinoma of the colon: Results from national surgical adjuvant breast and bowel project C-04. J Clin Oncol 1999;17:3553-9.
6. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dfose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15:246-50.
7. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939-44.
8. De Gramont A, Bosset J-F, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. J Clin Oncol 1997;15:808-15.
9. Andre T, Colin P, Louvet C, et al. Phase III trial (GERCOR C96.1) comparing bimonthly LV5FU2 to monthly 5FU-leucovorin high-dose (LV hd) in patients with Dukes' B2 and C colon cancer. Proc Am Soc Clin Oncol 2002;21:529.
10. Schilsky RL, Levin J, West WH, Wong A, Colwell B, Thirlwell MP, et al. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 2002;20:1519-26.
11. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3617-27.
12. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282-92.
13. Sakamoto J, Ohashi Y, Hamada C, Buyse M, Burzykowski T, Piedbois P. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004;22:484-92.
14. Sakamoto J, Hamada C, Kodaira S, Nakazato H, Ohashi Y. Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: Individual patient data meta-analysis of randomized trials. Jpn J Clin Oncol 1999;29:78-86.
15. Hoshi A, Iigo M, Yoshida M, Kuretani K. Antitumor activity of carbamoyl derivatives of 5-fluorouracil by oral administration. Jpn J Cancer Res 1975;66:673-4.
16. Hoshi A, Iigo M, Nakamura A, Yoshida M, Kuretani K. Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in a variety of experimental tumors. Jpn J Cancer Res 1976;67:725-31.
17. HCFU Clinical Study Group. Absorption and excretion of new oral antitumor drug, 1-hexylcarbamoyl-5-fluorouracil (HCFU), in cancer patients. Jpn J Clin Oncol 1980;10:83-92.
18. Iigo M, Hoshi A, Nakamura A, Kuretake K. Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety mouse tumors. Cancer Chemother Pharmacol 1978;1:203-8.
19. Koyama Y. 1-hexylcarbamoyl-5-fluorouracil (HCFU): A masked 5-fluorinated pyrimidine. Cancer Treat Rev 1981;8:147-51.
20. Davis HL. Chemotherapy of large bowel cancer. Cancer 1982;50:2638-46.
21. Buroker T, Padilla F, Groppe C, Guy G, Quagliana J, McCracken J, et al. Phase II evaluation of ftorafur in previously untreated colorectal cancer. Cancer 1979;44:48-51.
22. Sakamoto J, Kodaira S, Hamda C, et al. An individual patient data meta-analysis of long supported adjuvant chemotherapy with oral carmofur in patients with curatively resected colorectal cancer. Oncol Rep 2001;8:697-703.
23. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: A systematic overview of 8507 patients from 22 randomized trials. Lancet 2001;358:1291-304.
24. Ito K, Yamaguchi A, Mura K, et al. Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the First Study for Colorectal Cancer. J Surg Oncol 1996;62:4-9.
25. Ito K, Yamaguchi A, Miura K, et al. Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: Five-year follow-up. Tokai HCFU study Group-Third Study on Colorectal Cancer. J Surg Oncol 1996;63:107-11.
26. Sugimachi K, Maehara Y, Ogawa M, et al. Postoperative chemotherapy for colorectal cancer by combining 5-fluorouracil infusion and 1-hexylcarbamoyl-5-fluorouracil administration after curative resection. Cancer 1996;77:36-43.
27. Yasutomi M, Takahashi T, Kodaira S, et al. Prospective controlled study on the usefulness of carmofur as a postoperative adjuvant chemotherapy of colorectal cancer. Jpn J Cancer Chemother 1997;24:1953-60 (in Japanese).
28. Japanese foundation for multidisciplinary treatment of cancer. Report of Project #15, Tokyo, Japan 1999 (in Japanese).
29. Iwagaki H. Consideration of Post-operative Adjuvant Chemotherapy for Colorectal Cancer with 5-Fluorouracil (5-FU) Infusion Combined with 1-Hexylcarbamoyl-5-fluorouracil (HCFU) Oral Administration after Curative Resection. Proceedings of the Japan Society of Coloproctology, Yokohama 2002 (in Japanese).
30. Matsubara H, Okuyama K, Koide Y, et al. Consideration of Postoperative Adjuvant Chemotherapy in Combination Study. Proceedings of the Japanese Society for Cancer of the Colon and Rectum, Tokyo 1994 (in Japanese).
31. Ito T, Morita T, Sasaki M, et al. Postoperative Adjuvant Chemotherapy when Histologic Grade of Malignancy for Colorectal Cancer was Preclassified. Proceedings of the Japanese Society for Cancer of the Colon and Rectum, Tokyo 1999 (in Japanese).
32. Morioka Y, Muto T, Toyama J, et al. Postoperative adjuvant chemotherapy with HCFU (Carmofur) for colorectal cancer. Jpn J Cancer Clin 1989;35:1031-41 (in Japanese).
33. Takagi K, Fujimoto N, Fukushima Y, et al. Effect of Postoperative Adjuvant Chemotherapy for Colorectal Cancer. Proceedings of the Japanese Society for Cancer of the Colon and Rectum, Tokyo 1994 (in Japanese).
34. Kouno H, Tahara H, Sudou I, et al. Signification of Adjuvant Chemotherapy After Liver Metastasis of Colorectal Cancer Resection. Proceedings of the Japanese Society for Cancer of the Colon and Rectum, Tokyo 1994 (in Japanese).
35. Noda N, Sugihara K, Moriya N, et al. Consideration of Effect of Adjuvant Chemotherapy after Liver Metastasis of Colorectal Cancer Resection Curatively. Proceedings of the Japanese Society for Cancer of the Colon and Rectum, Tokyo 1994 (in Japanese).
36. Cooperative Study Group of Kyushu and Chugoku for HCFU Adjuvant Chemotherapy. Mitomycin C plus HCFU adjuvant chemotherapy for noncuratively resected cases of colorectal cartinoma (Second report): 5-year survival rate. Jpn J Cancer Chemother 1989;16:333-9 (in Japanese).
37. Nishida O, Osawa S, Omori K, et al. Assessment of Immuno-chemotherapy for Noncuratively Resected and Nonresected Patients for Colorectal Cancer. Proceedings of the Japan Society of Clinical Oncology, Niigata 1988 (in Japanese).
38. Fujii H, Inaji N, Nakajima Y, et al. Comparative Study of the Effect of Preoperative Chemotherapy for Colorectal Cancer. Proceedings of the Japan Society of Clinical Oncology, Hiroshima 2002 (in Japanese).
39. Kotake K, Oyama Y, Shida S, et al. Neo-adjuvant chemotherapy with carmofur for colorectal cancer - a multi-institutional randomized controlled study. Jpn J Cancer Chemother 2002;29:1917-24 (in Japanese).
40. Fujii Y, Akiyama N, Eriguchi M, et al. Efficacy of carmofur (HCFU) for colorectal carcinoma - comparison of continues and intermittent administration. Jpn J Cancer Clin 1993;39:905-9 (in Japanese).
41. Takano S, Ogawa M. Consideration of Optimum Administration Period for HCFU in Postoperative Adjuvant Chemotherapy for Colorectal Cancer. Proceedings of the Japanese Society for Cancer of the Colon and Rectum, Tokyo 1994 (in Japanese).
42. Ito K, Okushiba T, Ohno K, et al. Comparative study of administration period in postoperative adjuvant chemotherapy with HCFU for colorectal cancer. Jpn J Gastroenterol Surg 2000;33:1339 (in Japanese).
43. Ito K, Kato T, Koeke A, et al. Optimum duration of oral adjuvant chemotherapy of HCFU for colorectal cancer; review of 5-year follow-up. Anticancer Res 2000;20:4681-6.
44. Nakamura T, Ohno M, Tabuchi Y, et al. Optimum duration of oral adjuvant chemotherapy with Carmofur in the colorectal cancer patients: The Kansai Carmofur Study Group trial III. Int J Oncol 2001;19:291-8.
45. Watanabe T, Takagi H, Ichihashi, et al. Postoperative Adjuvant Chemotherapy with HCFU (Carmofur) and PSK for Colorectal Cancer, 6-year Follow-up. Proceedings of the Japan Society of Clinical Oncology, Niigata 1988 (in Japanese).
46. Iwagaki H, Tanaka N, Esato K, et al. Randomized controlled trial of 5-fluorouracil (5-FU) infusion combined with 1-hexylcalbamoil-5-fluorouracil (HCFU) oral administration and HCFU alone as postoperative adjuvant chemotherapy for colorectal cancer. Anticancer Res 2000;20:3727-34.
47. Iwagaki H, Tanaka N, Esato K, et al. Post-operative adjuvant chemotherapy for colorectal cancer with 5-fluorouracil (5-FU) infusion combined with 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration after curative resection. Anticancer Res 2001;21:4163-8.
48. Kobayashi S, Kameyama M, Imaoka M, et al. Comparative Study of the Combined Effect of HCFU + Dipyridamole (DP) in Colorectal Carcinoma. Proceedings of the Japanese society for Cancer of the Colon and Rectum 1999 (in Japanese).
49. Iwamoto K, Saito T, Kunii Y, et al. Effect of Postoperative Adjuvant Chemotherapy with HCFU, MMC and 5FU for Colorectal Cancer. Proceedings of the Japanese Society for Cancer of the Colon and Rectum 1999 (in Japanese).
50. Kobashi S, Sato Y, Kondo M, et al. Consideration of Postoperative Adjuvant Chemotherapy for Colorectal Cancer, Cur A and B with HCFU or UFT Mono-therapy vs. Combined of 5FU Continuous Infusion. Proceedings of the Japanese Society for Cancer of the Colon and Rectum 1999 (in Japanese).
51. Japanese foundation for multidisciplinary treatment of cancer. Report of Project #7. Tokyo, Japan 1996 (in Japanese).
52. Ito K, Yamaguchi A, Miura K, et al. Effect of oral adjuvant therapy with Carmofur (HCFU) for distant metastasis of colorectal cancer. Int J Clin Oncol 1996;63:107-11.
53. Maehara Y, Sugimachi K, Ogawa M, et al. Postoperative adjuvant chemotherapy with 1-hexylcalbamoil-5-fluorouracil in patients in colorectal cancer and at a high risk for recurrence. Anticancer Res 1998;18:4629-34.
54. Kanno H, Yoden Y, Ohashi S, et al. Comparative study of the combined effect of HCFU and dipyridamole (DP) in colorectal carcinoma - TS inhibition rate. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma. Gan To Kagaku Ryoho 1996;23:715-20 (in Japanese).
55. Koyama Y. (Cooperative Study Group of HCFU) Phase II Study of a new fluorinated pyrimidine, 1-hexylcarbamoyl-5-fluorouracil (HCFU). Jpn J Cancer Chemother 1980;7:1181-90 (in Japanese).
56. Nakanishi M, et al. The experience of using HCFU, a new anticancer drug. Jpn Pharmacol Ther 1980;8:1211 (in Japanese).
57. Yokoyama M, Okei A. Combination Therapy with Mitomycin C(MMC)/ Carmofur(HCFU) for Progressive Gastrointestinal Cancer - Report of Tohoku Study Group. Proceedings of the Japan Society of Clinical Oncology 1984 (in Japanese).
58. Takashima S, Kinami Y, Kiriyama M, et al. Distribution of 1-hezycarbamoyl-5-fluorouracil in rats and human patients, and clinical results in patients with colorectal cancer. Jpn J Cancer Chemother 1986;13:549-55 (in Japanese).
59. Iwahiro K, Inoue K, Akasaka S, et al. Immuno-chemotherapy with the combined of rentinum, HCFU and MMC. Prog Med 1987;7:1711-4 (in Japanese).
60. Rino Y, Joujima T, Abe M, et al. A case of sigmoid colon cancer with lung metastases effectively treated with HCFU and PSK. Biotherapy 1992;6:1331-3.
61. Matsuda T, Mabuchi K, Kitaoka H, et al. A case of multiple liver metastases showing good response by administration of carmofur alone in an aged patient with colorectal cancer. Jpn J Cancer Chemother 1999;26:357-9 (in Japanese).
62. Miyauchi M, Yamamoto N, Matsumoto M, et al. Comparative clinical study on 5-FU concentrations for oral HCFU and I.V. 5-FU. Jpn J Cancer Chemother 2000;27:1011-4 (in Japanese).
63. Mori T. Review of comparative studies of postoperative adjuvant chemotherapy after curativety resected colorectal cancer in Japan. Jpn J Cancer Chemother 2002;29:1532-9.
64. Oxman AD, Clarke MJ, Stewart LA. From science to practice. Meta-analyses using individual patient data are needed. J Am Med Assoc 1995;274:845-6.
65. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. Stat Med 1995;14:2057-79.
66. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 1999;28:1-9.
67. Steinberg KK, Smith SJ, Stroup DF, et al. Comparison of effect estimates for a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies. Am J Epidemiol 1997;145:917-25.